I. Laurén

Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients.

M. Höglund, M. Cragg, G. Ullenhag, 2020, International immunopharmacology.

Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab

J. Burman, I. Pavlović, Andreas Tolf, 2022, JAMA network open.

Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients.

M. Höglund, M. Cragg, G. Ullenhag, 2020, International immunopharmacology.

Long‐term SARS‐CoV‐2‐specific and cross‐reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology

P. Dönnes, H. Tegel, M. Hedhammar, 2022, Immunity, inflammation and disease.

An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses

P. Dönnes, S. Hober, J. Klingström, 2021, PloS one.

Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID‐19

P. Dönnes, H. Tegel, M. Hedhammar, 2021, Journal of internal medicine.

Fed-batch production assessment of a tetravalent bispecific antibody: a case study on piggyBac stably transfected HEK293 cells.

H. Persson, A. Olsson, L. Dahllund, 2021, New biotechnology.